Free shipping on orders over $200
Free shipping on orders over $200
Molecular Weight
Purity
Storage
Appearance
Solubility
01
This three-component research blend contains Cartalax (10 mg), TB-500 (5 mg) and BPC-157 (5 mg) in a single 20 mg lyophilized material. Cartalax is the tripeptide Ala-Glu-Asp (AED) from the Khavinson series of short-peptide bioregulators; TB-500 is synthetic thymosin β4; and BPC-157 is the proline-rich 15-residue peptide.
The components span about 333 to 4963 g/mol, and because the smallest is loaded most heavily, the molar amounts are very unequal: roughly 30 µmol Cartalax, 3.5 µmol BPC-157 and 1 µmol TB-500 per vial. This makes the blend a compact test sample for methods that must cover a wide mass and concentration range. It is supplied as a reference material for in vitro and analytical research only.
02
The three components differ in size, charge and structure.
Cartalax (10 mg)
Ala-Glu-Asp, C₁₂H₁₉N₃O₈, 333.3 g/mol. Very small and acidic (net charge about −2), with no aromatic residues. No CAS number has been assigned; it is identified by sequence, formula and mass.
TB-500 (5 mg)
Synthetic thymosin β4, 43 residues with an acetylated N-terminus (4963.4 g/mol). Rich in charged residues (nine lysines, eight glutamates), with Met6 as its main oxidation site and Phe12 as its only aromatic residue. Largely unstructured in solution.
BPC-157 (5 mg)
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (1419.5 g/mol): proline-rich and acidic, with no aromatic or sulfur-containing residues. Its Asp10-Asp11 pair is its main weak point.
Molar amounts
Per 20 mg vial: about 30 µmol Cartalax, 3.5 µmol BPC-157 and 1.0 µmol TB-500, a ratio of roughly 30 : 3.5 : 1.
03
Research interest focuses on analytical and stability behaviour across a wide range.
Wide concentration range
With about a 30-fold molar excess of Cartalax over TB-500, simultaneous quantification needs calibration spanning roughly two orders of magnitude and good sensitivity for TB-500 at the low end.
Separate degradation markers
Each component has its own marker: Asp-related changes in Cartalax, Met6 sulfoxide (+16 Da) in TB-500, and isoaspartate at Asp10-Asp11 in BPC-157. These fall in different mass and retention regions, so one stability-indicating run can follow all three.
Combining peptide families
The blend combines a Khavinson-type short bioregulator with two larger peptides from separate research areas. Each component’s research background is described on its own reference page or, for Cartalax, in the bioregulator literature. No claims are made for the combination.
04
Wide-range HPLC methods
Developing gradients that retain the very polar Cartalax while still eluting and resolving TB-500 with good peak shape.
Wide-pore column checks
Confirming that a 300 Å wide-pore column suited to TB-500 still resolves the small Cartalax and mid-sized BPC-157.
Multi-charge-state MS
Checking that a method correctly handles singly charged (Cartalax), doubly charged (BPC-157) and highly charged (TB-500) ions in one run.
Multi-marker stability
Monitoring three independent degradation markers in parallel under heat, humidity, pH and oxidative stress.
05
Storage
Store the sealed vial at −20 °C, desiccated and protected from light. Moisture uptake promotes aggregation of TB-500; let the vial reach room temperature before opening.
Reconstitution
Dissolve in water or a mild buffer, adding solvent slowly down the side of the vial and swirling gently. Vigorous shaking can aggregate TB-500.
Choosing pH
Both Cartalax and BPC-157 contain aspartate. Asp isomerisation through a succinimide is fastest at mildly acidic pH (around 4–6), and strong acid also cleaves Asp-containing bonds. A near-neutral pH (about 6.5–7.5), kept cold, is the safest choice for all three.
Oxidation
TB-500’s Met6 is the only oxidation-prone site in the blend; trace metals, oxygen and light accelerate it. Use degassed buffers where oxidation matters.
Solutions
Aliquot and freeze, and avoid repeated freeze–thaw cycles. Use low-binding polypropylene tubes; at low concentrations, losses of TB-500 to surfaces can be significant.
06
Each component is identified and quantified separately.
HPLC
A wide-pore (300 Å) C18 column with a shallow acetonitrile/0.1% TFA gradient at elevated temperature (about 40–60 °C) suits TB-500. Start at very low organic content so that Cartalax is retained away from the solvent front. Detect at 205–214 nm; only TB-500 has an aromatic residue (Phe12), so 280 nm is of little use.
Mass spectrometry
Cartalax gives [M+H]⁺ at m/z 334.1; BPC-157 mainly [M+2H]²⁺ at m/z 710.4 and [M+3H]³⁺ at 473.9 (monoisotopic); TB-500 a +4 to +7 envelope (about m/z 710–1242) that deconvolutes to 4963.4 Da. The three are easy to tell apart by their charge states.
Ratio verification
Each component is quantified against its own reference standard by external calibration covering its concentration range. Acceptance limits are set in the lot specification.
Stability markers
Cartalax Asp-related variants, TB-500 Met6 sulfoxide (+16 Da) and BPC-157 isoAsp variants (same mass, different retention).
07
Three: Cartalax (Ala-Glu-Asp, 10 mg), TB-500 (synthetic thymosin β4, 5 mg) and BPC-157 (5 mg), giving 20 mg per vial.
It is a formulation choice. Because the components differ so much in size, the molar picture is very different: about 30 µmol Cartalax, 3.5 µmol BPC-157 and 1 µmol TB-500 per vial.
All three blends contain BPC-157 and TB-500. GLOW adds GHK-Cu, and KLOW adds GHK-Cu and KPV. This blend instead adds the short bioregulator Cartalax and contains no copper.
Store the sealed vial at −20 °C, desiccated and protected from light. Reconstitute in water or mild buffer at near-neutral pH, adding the solvent slowly and swirling gently; keep the solution cold and use it promptly or freeze aliquots.
Reversed-phase HPLC on a wide-pore C18 column at elevated temperature, starting at low organic content and detecting at 205–214 nm, combined with LC-MS. Each component is quantified against its own reference standard.
No. CAS 205640-90-0 belongs to orexin A (hypocretin-1), a much larger neuropeptide. Cartalax (Ala-Glu-Asp) has no assigned CAS number and is identified by its sequence, formula C₁₂H₁₉N₃O₈ and mass.
No. It is supplied strictly as a reference material for laboratory and analytical research and is not for human or animal use.
Cartalax + TB-500 + BPC-157 Blend Research Reference. (2026). Pure Peptides Labs Research Catalogue. Retrieved from https://purepeptideslabs.net/research-catalogue/proprietary-research-blends/cartalax-tb-500-bpc-157-blend/
Materials listed on this platform are supported by independent testing and published documentation for laboratory research contexts.
